Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia
Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia
Active, not recruiting · NCT03834961 · Registry updated 2025-12-02Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia | Neoplasms by Site, central nervous system cancer, congenital fibrosarcoma, neoplasm, nervous system disorder | Active, not recruiting | Phase 2 | 2025-12-02 | NCT03834961 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Children's Oncology Group | 79 |
| National Cancer Institute (NCI) | 3015 |
80 results · Page 1 of 4
Research sites
Swipe the table sideways for more columns.